Samsung Biologics

12 articles about Samsung Biologics

• Samsung Biologics reports third quarter 2023 financial results

  10/25/2023

  Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the third quarter of fiscal year 2023.

• Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma's portfolio companies

  10/23/2023

  Samsung Biologics and Kurma Partners announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners' portfolio companies.

• Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

  9/18/2023

  Samsung Biologics announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance.

• 

  Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody

  9/18/2023

  The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.

• Samsung Biologics appoints new leadership to oversee quality and regulatory affairs

  8/24/2023

  Samsung Biologics, a global contract development and manufacturing organization, announced the appointments of Gail Ward as Executive Vice President and Head of the Quality Center, and Sojeong Lee as Vice President and Head of Regulatory Affairs.

• Samsung Biologics Reports Second Quarter 2023 Financial Results

  7/26/2023

  Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the second quarter of fiscal year 2023.

• Samsung Biologics releases 2023 ESG Report, reaffirming its commitment to net-zero progress and corporate social responsibility

  7/18/2023

  Samsung Biologics, a global contract development and manufacturing organization, released its 2023 Environmental, Social and Governance Report.

• 

  Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M

  7/5/2023

  The pharmaceutical giant is tapping the world’s largest biomanufacturing facility operated by Samsung Biologics for biosimilar production.

• Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

  6/6/2023

  While attending the 2023 BIO International Convention, Samsung Biologics, a leading contract development and manufacturing organization, revealed details of the company's future expansion plan to have its new fifth plant operational by April 2025.

• Samsung Biologics Reports First Quarter 2023 Financial Results

  4/24/2023

  Samsung Biologics, the world's leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2023.

• Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

  3/17/2023

  Samsung Biologics, a leading contract development and manufacturing organization, announced that the company will commence the construction of a fifth plant as part of its strategic expansion in response to increased market demand.

• Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results

  1/27/2023

  Samsung Biologics, the world's leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year 2022.